New lupus drug candidate enters early human testing
NCT ID NCT07564596
First seen May 04, 2026 · Last updated May 11, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called budoprutug (TNT119) in 30 adults with active lupus who haven't responded well to standard treatments. The drug aims to reduce disease activity by targeting and depleting certain immune cells. The main goals are to check safety, find the right dose, and see early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.